Fig 1: Expression of the MMP2 and MMP9 in kidneys of BW mice.Data demonstrate an insignificant increase in renal MMP2, but not in MMP9 mRNA levels in Group 3 mice compared with mice from Group 1 and 2 (A), and a corresponding increase in MMP2 protein (western blot, B) or in activated MMP2 (zymography, C). Serum concentrations of MMP2 and MMP9 were stable in all stages of the disease as demonstrated by quantitative ELISA for MMP2 and MMP9 (Figure 3D). In agreement with the hypothesis that MMP2 gene expression is linked to activation of TLRs, TLR8 correlates significantly with expression of MMP2 (r = 0,63, p<0,001, E).
Fig 2: IFN-α therapy induces TLR7/8 expression on myeloid cells.a, Differential expression of Tlr7 in myeloid cells identified by scRNA-Seq in skin-draining lymph nodes after IFN-α treatment (10.000 U, 4 h, s.c.) of mice. Gene expression data extracted from https://www.immunedictionary.org/app/home. b, Tlr7 expression in sorted myeloid cells analyzed by Microarray. Gene expression data extracted from: http://rstats.immgen.org/Skyline_microarray/skyline.html?datagroup=IFN. IFN-α treatment: (10.000 U, 2 h). c, DCs were generated from bone marrow that was supplemented with FLT3L and Tlr8 mRNA expression was analyzed using qRT–PCR. Cells were treated for 24 h with IFN-α (500 or 5000 U/mL), or with IMQ (2.5 µg/mL). In c, d n = 3 mice per group from 1 experiment. d, Tlr8 mRNA expression was assessed in murine bone-marrow-derived macrophages using qRT–PCR. Macrophages were treated as described in (c). e, Heatmap depicts TLR7 expression on myeloid cells within tumor-draining lymph nodes. Treatments are indicated in color-coded rectangles above the heatmap. The fold change of the geometric mean fluorescence intensity (gMFI) of TLR7 on indicated myeloid cells of treated mice compared to the control is shown. In e–g n = 3 mice per group from 1 experiment. f, Spleens were analyzed for TLR7 expression. Heatmap was plotted as described in (e). g, Small intestines were analyzed for TLR7 expression. Heatmap was plotted as described in (e). h, Tlr8 mRNA expression plotted against a human myeloid cell signature gene (Cd1c) in a subset of melanoma patients included in the TCGA database. The subset consisted of patients who received IFN-α prior to biopsy (n = 29) and a control group who did not receive IFN-α (n = 14). i, Correlation plot of Tlr8 to Cd68 in a subset of melanoma patients from the TCGA database, as described in (h). Bar graphs are plotted as mean ± SEM. Dots in c and d represent biological replicates. Correlation is shown in a xy-plot with a linear regression. Heatmaps are color-coded (blue = low, red = high value). P values were calculated using unpaired, two-tailed t-tests (e–g), one-way ANOVA with Tukey´s post-test (c, d) and two-tailed Pearson´s correlation test (h, i). * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001. Source data
Fig 3: Expression patterns of DNaseI, TLR7–9 in kidneys from patients with lupus nephritis.A profound silencing of DNaseI gene expression in kidneys with membranoproliferative lupus nephritis (ISN/RPS class IV, A) compared with DNaseI mRNA levels in control kidneys. Western blot analyses of renal proteins demonstrated a single band corresponding to the MW of human DNaseI (B). Low band intensities were solely found in the kidney samples that demonstrated considerably reduced DNaseI mRNA levels (LN 1–3, A and B). Similarly, immunohistochemistry analyses of kidney sections demonstrated strong staining intensity of the DNaseI protein in normal control kidneys (C) and in ISN/RPS class II kidneys (C). In ISN/RPS class IV kidneys, DNaseI staining was barely detectable (C), in agreement with the low DNaseI mRNA levels in these patients. Control analyses in other renal diseases (like diabetic nephrosclerosis or membranoproliferative glomerulonephritis type 2) demonstrated DNaseI staining intensity similar to that in normal kidneys, and kidneys with ISN/RPS class II lupus nephritis (C). The qPCR analyses revealed that TLR7 and TLR 8 were up-regulated in class IV nephritis, although without reaching statistical significance (D). The TLR 9 and Clec4e (data not shown) mRNA levels did not differ at all from the control group. In harmony with this, immunohistochemical staining of kidneys with class IV lupus nephritis revealed increased staining intensity of TLR8 (E). An unpaired t-test is performed (*p<0,05).
Fig 4: IFN-α therapy induces TLR7 on myeloid cells in tumor stroma.a, TLR7 immunohistochemistry staining of human skin. To the left: Representative pictures before and during IFN-α therapy. Insets show enlarged views of the marked areas. To the right: Quantification of TLR7-positive cells is presented as a percentage of total cells. Scale bar: 100 µm. In a, b n = 5 individuals. b, TLR8 staining of human skin of patients undergoing IFN-I therapy. On the left are representative pictures. Insets provide enlarged views of the marked areas. On the right is the quantification of TLR8-positive cells which is shown as percentage of total cells. Scale bar: 100 µm. c, Multiplex immunofluorescence analysis of melanoma samples from a cohort of five patients undergoing IFN-α therapy. The staining panel included antibodies against CD1a, CD1c, CD68, CD141, and TLR7. Representative images show the upper dermis of a patient before (upper panels) and during IFN-α therapy (lower panels). On the left, a full-color panel, and on the right TLR7 in combination with selected markers is shown. Insets show enlarged views of the marked areas, and highlight cells that are positive for TLR7 and/or one of the myeloid cell markers. Magnification: 10x (Zoom), Scale bar: 50 µm, Insets: 10 µm. In d n = 5 individuals. d, Quantification of TLR7-expressing cells positive for CD1a, CD1c, CD68 and CD141 was performed in the upper dermis in immunofluorescence staining’s described in (c). N.D. = not detectable. Data are plotted as dots and lines. Dots in a, b and represent individuals. P values were calculated using paired, two-tailed t-test (a, b and d). Source data
Supplier Page from Abcam for Anti-TLR8 antibody